Login / Signup

Budget Impact of the Oncotype DX Breast Recurrence Score ® Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in Germany.

Michael Patrick LuxChristof MinartzHarald Müller-HuesmannMarianar Felicia SandorSabine Radeck-KnorreAljoscha Steffen Neubauer
Published in: Breast care (Basel, Switzerland) (2023)
Analogous to the pN0 situation, this budget impact model demonstrates that the Oncotype DX Breast Recurrence Score test can also reduce healthcare costs in Germany in treatment of node-positive (pN1: 1-3 positive lymph nodes) patients by minimizing both unnecessary chemotherapy and undertreatment. Additional benefits to patients would include reduced morbidity and improved quality of life for those patients who can safely avoid chemotherapy or undertreatment.
Keyphrases
  • lymph node
  • end stage renal disease
  • healthcare
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • patient reported
  • locally advanced
  • early stage
  • free survival